PAVmed to Present at Dawson James Securities 3rd Annual Small Cap Growth Conference
October 10 2017 - 7:30AM
Business Wire
PAVmed Inc. (NASDAQ:PAVM; PAVMW), a highly
differentiated, multi-product medical device company, today
announced that Dennis McGrath, PAVmed’s Chief Financial Officer,
will present at the Dawson James Securities 3rd Annual Small Cap
Growth Conference on Thursday, October 19, 2017 at 1:00 p.m.
Eastern time. Mr. McGrath will provide a corporate overview,
discuss the Company’s innovative business model and review PAVmed’s
lead products. The conference will be held at the Wyndham Grand
Hotel in Jupiter, Florida on October 18-19, 2017.
To access the live webcast of the presentation, please click
here. A replay will be available following the presentation.
About PAVmed Inc.
PAVmed Inc. (Nasdaq: PAVM, PAVMW) is a highly differentiated,
multi-product medical device company employing a unique business
model designed to advance products from concept to
commercialization much more rapidly and with significantly less
capital than the typical medical device company. This proprietary
model enables PAVmed to pursue an expanding multi-product pipeline
strategy with a view to enhancing and accelerating value creation.
PAVmed’s diversified pipeline of products address unmet clinical
needs, have attractive regulatory pathways and market opportunities
and encompass a broad spectrum of clinical areas including carpal
tunnel syndrome (CarpX™), medical infusions (NextFlo™ and
NextCath™), interventional radiology (PortIO™ and NextCath), tissue
ablation and cardiovascular intervention (Caldus™) and pediatric
ear infections (DisappEAR™).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171010005314/en/
InvestorsLHA Investor RelationsKim
Sutton Golodetz, 212-838-3777kgolodetz@lhai.comorinfo@pavmed.comorMediaRooneyPartnersThomas Hynes,
212-223-0651thynes@rooneyco.com
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Mar 2024 to Apr 2024
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Apr 2023 to Apr 2024